← Back to Clinical Trials
Recruiting Phase 3 NCT06836492
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Trial Parameters
Condition Rhabdomyosarcoma
Sponsor Yizhuo Zhang
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 300
Sex ALL
Min Age 0 Years
Max Age 18 Years
Start Date 2017-01-30
Completion 2029-09
All Conditions
Interventions
VAC，VAC/VII，CAV/IE
Brief Summary
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
Eligibility Criteria
Inclusion Criteria: 1. 0 years \< age \< 18 years old, regardless of gender; 2. Tumor patients diagnosed by histopathology or bone marrow cytology; 3. Patients are treated for the first time; 4. ECoG score ≤ 2; 5. The expected survival time is more than 8 months; 6. Patient's parent or guardian signs informed consent. Exclusion Criteria: 1. Combined with immunodeficiency disease 2. Second tumor
Related Trials
NCT06441331
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Th
View Trial →
NCT06865664
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refract
View Trial →
NCT06541262
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
View Trial →